PUBLISHER: The Business Research Company | PRODUCT CODE: 1947002
PUBLISHER: The Business Research Company | PRODUCT CODE: 1947002
A positron emission tomography (PET) radiotracer is a radioactive substance used in PET imaging. This radiotracer is administered to a patient via injection, where it binds to specific biological targets, enabling the PET scanner to visualize metabolic activity and diagnose conditions such as cancer or neurological disorders.
The primary types of PET radiotracers include F-18 (Fluorodeoxyglucose 18), Ga-68 (Fibroblast Activation Protein Inhibitor), and others. F-18 (Fluorodeoxyglucose 18) radiotracers are radioactive glucose analogs utilized in PET imaging to evaluate metabolic activity in tissues, particularly for cancer detection. These radiotracers are applied across various medical fields, including oncology, cardiology, gastrointestinal disorders, endocrine issues, and neurology. They are used by end-users such as hospitals and diagnostic centers, among others.
Tariffs are impacting the PET radiotracer market by increasing costs of imported radioisotopes, synthesis modules, cyclotron components, and quality control equipment. Hospitals and diagnostic centers in North America and Europe are most affected due to dependence on imported isotopes and production technologies, while Asia-Pacific faces higher manufacturing input costs. These tariffs are increasing operational expenses and affecting tracer availability. However, they are also encouraging domestic isotope production, regional radiopharmacy expansion, and localized supply chain development.
The positron emission tomography (pet) radiotracer market research report is one of a series of new reports from The Business Research Company that provides positron emission tomography (pet) radiotracer market statistics, including positron emission tomography (pet) radiotracer industry global market size, regional shares, competitors with a positron emission tomography (pet) radiotracer market share, detailed positron emission tomography (pet) radiotracer market segments, market trends and opportunities, and any further data you may need to thrive in the positron emission tomography (pet) radiotracer industry. This positron emission tomography (pet) radiotracer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The positron emission tomography (pet) radiotracer market size has grown strongly in recent years. It will grow from $2.54 billion in 2025 to $2.78 billion in 2026 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to increasing cancer diagnosis rates, expansion of nuclear medicine facilities, established use of fdg-based imaging, availability of cyclotron infrastructure, growth of diagnostic imaging services.
The positron emission tomography (pet) radiotracer market size is expected to see strong growth in the next few years. It will grow to $3.95 billion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to increasing demand for precision diagnostics, rising investments in radiopharmaceutical R&D, expansion of theranostics applications, growing adoption of pet imaging in neurology and cardiology, increasing regulatory approvals for new tracers. Major trends in the forecast period include increasing development of target-specific radiotracers, rising adoption of pet imaging in oncology diagnostics, growing use of novel isotopes beyond fdg, expansion of personalized nuclear medicine applications, enhanced focus on short-half-life radiotracer production.
The rising prevalence of infectious diseases is expected to drive the growth of the positron emission tomography (PET) radiotracer market in the coming years. Infectious diseases are illnesses caused by pathogenic microorganisms, including bacteria, viruses, fungi, and parasites. The increasing occurrence of these diseases is attributed to factors such as climate change, urbanization, globalization, antibiotic resistance, and shifts in human behavior, all of which contribute to the spread of pathogens. PET radiotracers support the management of infectious diseases by enabling visualization of metabolic activity and inflammation, facilitating infection detection, evaluation of treatment response, and differentiation between infectious and non-infectious conditions, thereby improving patient outcomes. For example, in February 2024, a report published by the UK Health Security Agency, a UK-based government organization, indicated that tuberculosis (TB) cases in England rose by 10.7% in 2023, with 4,850 cases reported compared to 4,380 cases in 2022. Consequently, the growing burden of infectious diseases is contributing to the expansion of the PET radiotracer market.
Companies active in the positron emission tomography (PET) radiotracer market are increasingly focusing on the development of advanced diagnostic solutions, including PET imaging agents, to improve cancer detection and patient outcomes. PET imaging agents are radioactive substances used to visualize and quantify biological processes within the body during PET scans. For instance, in March 2023, IsoLogic Innovative Radiopharmaceuticals, a Canada-based radiopharmaceutical company, launched Illuccix, also referred to as the Ga-68 Gozetotide Preparation Kit (PSMA-11), in Canada. This prostate cancer imaging agent is designed to detect metastatic prostate cancer and supports physicians in identifying metastatic disease and guiding patient management decisions. It is indicated for use in patients suspected of having metastasis who are candidates for initial definitive therapy, as well as in individuals with suspected recurrence based on elevated serum prostate-specific antigen (PSA) levels.
In February 2023, Lantheus Holdings Inc., a US-based developer of diagnostic products, acquired Cerveau Technologies for an undisclosed amount. This acquisition is intended to strengthen Lantheus Holdings' imaging pipeline, particularly in the area of Alzheimer's disease diagnostics, by integrating Cerveau's MK-6240, a second-generation PET imaging agent that targets tau tangles in the brain. Cerveau Technologies Inc. is a US-based company involved in the development of positron emission tomography (PET) radiotracers.
Major companies operating in the positron emission tomography (pet) radiotracer market are Cardinal Health Inc., GE Healthcare Technologies Inc., Bracco Imaging S.p.A., Lantheus Holdings Inc., Jubilant Pharma Limited, SOFIE Biosciences, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Nordion Inc., Isologic Innovative Radiopharmaceuticals, ABX Advanced Biochemical Compounds GmbH, IBA Radiopharma Solutions S.A., ImaginAb Inc., Radiomedix Inc., Curium Pharma, Blue Earth Diagnostics Ltd., Eckert & Ziegler Radiopharma GmbH, Advanced Accelerator Applications (Novartis), Telix Pharmaceuticals Limited, PETNET Solutions Inc., Piramal Imaging
North America was the largest region in the positron emission tomography (PET) radiotracer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the positron emission tomography (pet) radiotracer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the positron emission tomography (pet) radiotracer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The positron emission tomography (PET) radiotracer market consists of sales of FDG (fluorodeoxyglucose), f-dopa (fluorodopa), C-11 methionine, C-11 methionine, F-18 naf (sodium fluoride), and C-11 choline. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Positron Emission Tomography (PET) Radiotracer Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses positron emission tomography (pet) radiotracer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for positron emission tomography (pet) radiotracer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The positron emission tomography (pet) radiotracer market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.